Document 1066 DOCN M9471066 TI Cationic liposomes for direct gene transfer in therapy of cancer and other diseases (Meeting abstract). DT 9409 AU Huang L; Gao X; Farhood H; Son K; Dept. of Pharmacology, Univ. of Pittsburgh Sch. of Medicine,; Pittsburgh, PA SO Gene Therapy for Neoplastic Diseases. June 26-29, 1993, Washington, DC, A5, 1993.. Unique Identifier : AIDSLINE ICDB/94698152 AB Cationic liposomes can mediate efficient delivery of DNA and DNA/protein complex to mammalian cells in vitro and in vivo. Cationic cholesterol derivatives mixed with phosphatidylethanolamine and sonicated to form small unilamellar vesicles can complex with DNA and mediate the entry into the cytosol from the endosome compartment. One of the liposome formulations, ie, DC-Chol liposomes, are used in a gene therapy clinical trial for melanoma. Recently, we exploited these cationic liposomes for the delivery of trans-activating protein factors to regulate and control the expression of delivered transgenes in a protein-dose dependent manner. Bacteriophage T7 RNA polymerase was co-delivered with a reporter gene under the control of T7 promoter to allow cytoplasmic expression of the gene. Human immunodeficiency virus-1 (HIV) trans-activating protein (tat) was also co-delivered with a reporter gene under the control of HIV-1 long terminal repeat. Finally, human tumor cells selected for cisplatin resistance, or isolated from patients who have failed cisplatin therapy are highly transfectable with cationic liposomes. These results suggest a serial therapy protocol with cisplatin and gene therapy for malignancy. DE Animal Cations Clinical Trials Gene Products, tat/GENETICS *Gene Therapy *Gene Transfer Human *Liposomes Melanoma/THERAPY Neoplasms/*THERAPY Phospholipids RNA Polymerases/GENETICS Tumor Cells, Cultured MEETING ABSTRACT SOURCE: National Library of Medicine. NOTICE: This material may be protected by Copyright Law (Title 17, U.S.Code).